Shingles Treatments

Shingles Treatments Comprehensive Study by Type (Antiviral Medications, Narcotic Medications, Anti-Inflammatory Medications, Antihistamines, Anticonvulsants, Creams, Others), Route of Administration (Oral, Injection), End User (Clinics, Hospitals, Diagnostic Centers, Home Care Settings) Players and Region - Global Market Outlook to 2030

Shingles Treatments Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Shingles Treatments
Shingles is a reactivation of the chickenpox virus in the body, causing a painful rash. Anyone who had chickenpox may develop shingles. It is still unidentified what reactivates the virus. The use of various drugs to treat shingles enables to provide relief from rashes. As per sources, about one million instances of shingles are detailed each year in the United States, and around one in every three individuals in the United States will create shingles in their lifetime. The risk of shingles increases with age, with most cases reported among people over 40 years old. This will drive the market growth in the forecast period

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Several companies are leaning toward inorganic growth strategies such as mergers & acquisitions to improve their market share and brand presence globally. The market is highly fragmented and consists of several manufacturers at the global and regional level competing to increase their market share in the respective regions Analyst at AMA Research estimates that United States and European Players will contribute the maximum growth to Global Shingles Treatments market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline PLC (United Kingdom), Foamix Pharmaceuticals Ltd (United States), Epiphany Biosciences Inc (United States), Merck & Co. (United States), Astellas Pharma Inc.(Japan), Novartis International AG (Switzerland) and F. Hoffmann-La Roche AG (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Beijing Minhai Biotechnology Co. (China), GeneOne Life Science, Inc. (South Korea), NAL Pharmaceuticals Ltd. (United States) and TSRL, Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Shingles Treatments market by Type (Antiviral Medications, Narcotic Medications, Anti-Inflammatory Medications, Antihistamines, Anticonvulsants, Creams and Others) and Region.



On the basis of geography, the market of Shingles Treatments has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Shingles Treatments market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Clinics will boost the Shingles Treatments market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
R&D investment in Drug Development

Market Growth Drivers:
Rising Pervasiveness Of Shingles and Demand For Antiviral to Reduce The Shingles Rash

Challenges:
Lack Of Guidance From Specialists In Choosing Appropriate Anticoagulant

Restraints:
High Cost Of Antibodies Is Restraining Vaccination

Opportunities:
Developing Interest For Antiviral Prescriptions And Over-The-Counter Pain Medicines and High Demand From Emerging Countries

Market Leaders and their expansionary development strategies
In September 2023, Biocryst Pharmaceuticals collaborates with leading academic research institutions to conduct further clinical trials on galidesivir and explore its potential for broader antiviral applications.
In November 2023, Biocryst Pharmaceuticals receives Breakthrough Therapy designation from the FDA for their oral antiviral medication galidesivir for treating acute shingles and PHN.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Shingles Treatments Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Antiviral Medications
  • Narcotic Medications
  • Anti-Inflammatory Medications
  • Antihistamines
  • Anticonvulsants
  • Creams
  • Others
By Route of Administration
  • Oral
  • Injection

By End User
  • Clinics
  • Hospitals
  • Diagnostic Centers
  • Home Care Settings

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Pervasiveness Of Shingles
      • 3.2.2. Demand For Antiviral to Reduce The Shingles Rash
    • 3.3. Market Challenges
      • 3.3.1. Lack Of Guidance From Specialists In Choosing Appropriate Anticoagulant
    • 3.4. Market Trends
      • 3.4.1. R&D investment in Drug Development
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Shingles Treatments, by Type, Route of Administration, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Shingles Treatments (Value)
      • 5.2.1. Global Shingles Treatments by: Type (Value)
        • 5.2.1.1. Antiviral Medications
        • 5.2.1.2. Narcotic Medications
        • 5.2.1.3. Anti-Inflammatory Medications
        • 5.2.1.4. Antihistamines
        • 5.2.1.5. Anticonvulsants
        • 5.2.1.6. Creams
        • 5.2.1.7. Others
      • 5.2.2. Global Shingles Treatments by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Injection
      • 5.2.3. Global Shingles Treatments by: End User (Value)
        • 5.2.3.1. Clinics
        • 5.2.3.2. Hospitals
        • 5.2.3.3. Diagnostic Centers
        • 5.2.3.4. Home Care Settings
      • 5.2.4. Global Shingles Treatments Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Shingles Treatments: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline PLC (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Foamix Pharmaceuticals Ltd (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Epiphany Biosciences Inc (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Astellas Pharma Inc.(Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis International AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Shingles Treatments Sale, by Type, Route of Administration, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Shingles Treatments (Value)
      • 7.2.1. Global Shingles Treatments by: Type (Value)
        • 7.2.1.1. Antiviral Medications
        • 7.2.1.2. Narcotic Medications
        • 7.2.1.3. Anti-Inflammatory Medications
        • 7.2.1.4. Antihistamines
        • 7.2.1.5. Anticonvulsants
        • 7.2.1.6. Creams
        • 7.2.1.7. Others
      • 7.2.2. Global Shingles Treatments by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Injection
      • 7.2.3. Global Shingles Treatments by: End User (Value)
        • 7.2.3.1. Clinics
        • 7.2.3.2. Hospitals
        • 7.2.3.3. Diagnostic Centers
        • 7.2.3.4. Home Care Settings
      • 7.2.4. Global Shingles Treatments Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Shingles Treatments: by Type(USD Million)
  • Table 2. Shingles Treatments Antiviral Medications , by Region USD Million (2018-2023)
  • Table 3. Shingles Treatments Narcotic Medications , by Region USD Million (2018-2023)
  • Table 4. Shingles Treatments Anti-Inflammatory Medications , by Region USD Million (2018-2023)
  • Table 5. Shingles Treatments Antihistamines , by Region USD Million (2018-2023)
  • Table 6. Shingles Treatments Anticonvulsants , by Region USD Million (2018-2023)
  • Table 7. Shingles Treatments Creams , by Region USD Million (2018-2023)
  • Table 8. Shingles Treatments Others , by Region USD Million (2018-2023)
  • Table 9. Shingles Treatments: by Route of Administration(USD Million)
  • Table 10. Shingles Treatments Oral , by Region USD Million (2018-2023)
  • Table 11. Shingles Treatments Injection , by Region USD Million (2018-2023)
  • Table 12. Shingles Treatments: by End User(USD Million)
  • Table 13. Shingles Treatments Clinics , by Region USD Million (2018-2023)
  • Table 14. Shingles Treatments Hospitals , by Region USD Million (2018-2023)
  • Table 15. Shingles Treatments Diagnostic Centers , by Region USD Million (2018-2023)
  • Table 16. Shingles Treatments Home Care Settings , by Region USD Million (2018-2023)
  • Table 17. South America Shingles Treatments, by Country USD Million (2018-2023)
  • Table 18. South America Shingles Treatments, by Type USD Million (2018-2023)
  • Table 19. South America Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 20. South America Shingles Treatments, by End User USD Million (2018-2023)
  • Table 21. Brazil Shingles Treatments, by Type USD Million (2018-2023)
  • Table 22. Brazil Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 23. Brazil Shingles Treatments, by End User USD Million (2018-2023)
  • Table 24. Argentina Shingles Treatments, by Type USD Million (2018-2023)
  • Table 25. Argentina Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 26. Argentina Shingles Treatments, by End User USD Million (2018-2023)
  • Table 27. Rest of South America Shingles Treatments, by Type USD Million (2018-2023)
  • Table 28. Rest of South America Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 29. Rest of South America Shingles Treatments, by End User USD Million (2018-2023)
  • Table 30. Asia Pacific Shingles Treatments, by Country USD Million (2018-2023)
  • Table 31. Asia Pacific Shingles Treatments, by Type USD Million (2018-2023)
  • Table 32. Asia Pacific Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 33. Asia Pacific Shingles Treatments, by End User USD Million (2018-2023)
  • Table 34. China Shingles Treatments, by Type USD Million (2018-2023)
  • Table 35. China Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 36. China Shingles Treatments, by End User USD Million (2018-2023)
  • Table 37. Japan Shingles Treatments, by Type USD Million (2018-2023)
  • Table 38. Japan Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 39. Japan Shingles Treatments, by End User USD Million (2018-2023)
  • Table 40. India Shingles Treatments, by Type USD Million (2018-2023)
  • Table 41. India Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 42. India Shingles Treatments, by End User USD Million (2018-2023)
  • Table 43. South Korea Shingles Treatments, by Type USD Million (2018-2023)
  • Table 44. South Korea Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 45. South Korea Shingles Treatments, by End User USD Million (2018-2023)
  • Table 46. Taiwan Shingles Treatments, by Type USD Million (2018-2023)
  • Table 47. Taiwan Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 48. Taiwan Shingles Treatments, by End User USD Million (2018-2023)
  • Table 49. Australia Shingles Treatments, by Type USD Million (2018-2023)
  • Table 50. Australia Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 51. Australia Shingles Treatments, by End User USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Shingles Treatments, by Type USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 54. Rest of Asia-Pacific Shingles Treatments, by End User USD Million (2018-2023)
  • Table 55. Europe Shingles Treatments, by Country USD Million (2018-2023)
  • Table 56. Europe Shingles Treatments, by Type USD Million (2018-2023)
  • Table 57. Europe Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 58. Europe Shingles Treatments, by End User USD Million (2018-2023)
  • Table 59. Germany Shingles Treatments, by Type USD Million (2018-2023)
  • Table 60. Germany Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 61. Germany Shingles Treatments, by End User USD Million (2018-2023)
  • Table 62. France Shingles Treatments, by Type USD Million (2018-2023)
  • Table 63. France Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 64. France Shingles Treatments, by End User USD Million (2018-2023)
  • Table 65. Italy Shingles Treatments, by Type USD Million (2018-2023)
  • Table 66. Italy Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 67. Italy Shingles Treatments, by End User USD Million (2018-2023)
  • Table 68. United Kingdom Shingles Treatments, by Type USD Million (2018-2023)
  • Table 69. United Kingdom Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 70. United Kingdom Shingles Treatments, by End User USD Million (2018-2023)
  • Table 71. Netherlands Shingles Treatments, by Type USD Million (2018-2023)
  • Table 72. Netherlands Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 73. Netherlands Shingles Treatments, by End User USD Million (2018-2023)
  • Table 74. Rest of Europe Shingles Treatments, by Type USD Million (2018-2023)
  • Table 75. Rest of Europe Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 76. Rest of Europe Shingles Treatments, by End User USD Million (2018-2023)
  • Table 77. MEA Shingles Treatments, by Country USD Million (2018-2023)
  • Table 78. MEA Shingles Treatments, by Type USD Million (2018-2023)
  • Table 79. MEA Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 80. MEA Shingles Treatments, by End User USD Million (2018-2023)
  • Table 81. Middle East Shingles Treatments, by Type USD Million (2018-2023)
  • Table 82. Middle East Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 83. Middle East Shingles Treatments, by End User USD Million (2018-2023)
  • Table 84. Africa Shingles Treatments, by Type USD Million (2018-2023)
  • Table 85. Africa Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 86. Africa Shingles Treatments, by End User USD Million (2018-2023)
  • Table 87. North America Shingles Treatments, by Country USD Million (2018-2023)
  • Table 88. North America Shingles Treatments, by Type USD Million (2018-2023)
  • Table 89. North America Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 90. North America Shingles Treatments, by End User USD Million (2018-2023)
  • Table 91. United States Shingles Treatments, by Type USD Million (2018-2023)
  • Table 92. United States Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 93. United States Shingles Treatments, by End User USD Million (2018-2023)
  • Table 94. Canada Shingles Treatments, by Type USD Million (2018-2023)
  • Table 95. Canada Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 96. Canada Shingles Treatments, by End User USD Million (2018-2023)
  • Table 97. Mexico Shingles Treatments, by Type USD Million (2018-2023)
  • Table 98. Mexico Shingles Treatments, by Route of Administration USD Million (2018-2023)
  • Table 99. Mexico Shingles Treatments, by End User USD Million (2018-2023)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Shingles Treatments: by Type(USD Million)
  • Table 108. Shingles Treatments Antiviral Medications , by Region USD Million (2025-2030)
  • Table 109. Shingles Treatments Narcotic Medications , by Region USD Million (2025-2030)
  • Table 110. Shingles Treatments Anti-Inflammatory Medications , by Region USD Million (2025-2030)
  • Table 111. Shingles Treatments Antihistamines , by Region USD Million (2025-2030)
  • Table 112. Shingles Treatments Anticonvulsants , by Region USD Million (2025-2030)
  • Table 113. Shingles Treatments Creams , by Region USD Million (2025-2030)
  • Table 114. Shingles Treatments Others , by Region USD Million (2025-2030)
  • Table 115. Shingles Treatments: by Route of Administration(USD Million)
  • Table 116. Shingles Treatments Oral , by Region USD Million (2025-2030)
  • Table 117. Shingles Treatments Injection , by Region USD Million (2025-2030)
  • Table 118. Shingles Treatments: by End User(USD Million)
  • Table 119. Shingles Treatments Clinics , by Region USD Million (2025-2030)
  • Table 120. Shingles Treatments Hospitals , by Region USD Million (2025-2030)
  • Table 121. Shingles Treatments Diagnostic Centers , by Region USD Million (2025-2030)
  • Table 122. Shingles Treatments Home Care Settings , by Region USD Million (2025-2030)
  • Table 123. South America Shingles Treatments, by Country USD Million (2025-2030)
  • Table 124. South America Shingles Treatments, by Type USD Million (2025-2030)
  • Table 125. South America Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 126. South America Shingles Treatments, by End User USD Million (2025-2030)
  • Table 127. Brazil Shingles Treatments, by Type USD Million (2025-2030)
  • Table 128. Brazil Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 129. Brazil Shingles Treatments, by End User USD Million (2025-2030)
  • Table 130. Argentina Shingles Treatments, by Type USD Million (2025-2030)
  • Table 131. Argentina Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 132. Argentina Shingles Treatments, by End User USD Million (2025-2030)
  • Table 133. Rest of South America Shingles Treatments, by Type USD Million (2025-2030)
  • Table 134. Rest of South America Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 135. Rest of South America Shingles Treatments, by End User USD Million (2025-2030)
  • Table 136. Asia Pacific Shingles Treatments, by Country USD Million (2025-2030)
  • Table 137. Asia Pacific Shingles Treatments, by Type USD Million (2025-2030)
  • Table 138. Asia Pacific Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 139. Asia Pacific Shingles Treatments, by End User USD Million (2025-2030)
  • Table 140. China Shingles Treatments, by Type USD Million (2025-2030)
  • Table 141. China Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 142. China Shingles Treatments, by End User USD Million (2025-2030)
  • Table 143. Japan Shingles Treatments, by Type USD Million (2025-2030)
  • Table 144. Japan Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 145. Japan Shingles Treatments, by End User USD Million (2025-2030)
  • Table 146. India Shingles Treatments, by Type USD Million (2025-2030)
  • Table 147. India Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 148. India Shingles Treatments, by End User USD Million (2025-2030)
  • Table 149. South Korea Shingles Treatments, by Type USD Million (2025-2030)
  • Table 150. South Korea Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 151. South Korea Shingles Treatments, by End User USD Million (2025-2030)
  • Table 152. Taiwan Shingles Treatments, by Type USD Million (2025-2030)
  • Table 153. Taiwan Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 154. Taiwan Shingles Treatments, by End User USD Million (2025-2030)
  • Table 155. Australia Shingles Treatments, by Type USD Million (2025-2030)
  • Table 156. Australia Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 157. Australia Shingles Treatments, by End User USD Million (2025-2030)
  • Table 158. Rest of Asia-Pacific Shingles Treatments, by Type USD Million (2025-2030)
  • Table 159. Rest of Asia-Pacific Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 160. Rest of Asia-Pacific Shingles Treatments, by End User USD Million (2025-2030)
  • Table 161. Europe Shingles Treatments, by Country USD Million (2025-2030)
  • Table 162. Europe Shingles Treatments, by Type USD Million (2025-2030)
  • Table 163. Europe Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 164. Europe Shingles Treatments, by End User USD Million (2025-2030)
  • Table 165. Germany Shingles Treatments, by Type USD Million (2025-2030)
  • Table 166. Germany Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 167. Germany Shingles Treatments, by End User USD Million (2025-2030)
  • Table 168. France Shingles Treatments, by Type USD Million (2025-2030)
  • Table 169. France Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 170. France Shingles Treatments, by End User USD Million (2025-2030)
  • Table 171. Italy Shingles Treatments, by Type USD Million (2025-2030)
  • Table 172. Italy Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 173. Italy Shingles Treatments, by End User USD Million (2025-2030)
  • Table 174. United Kingdom Shingles Treatments, by Type USD Million (2025-2030)
  • Table 175. United Kingdom Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 176. United Kingdom Shingles Treatments, by End User USD Million (2025-2030)
  • Table 177. Netherlands Shingles Treatments, by Type USD Million (2025-2030)
  • Table 178. Netherlands Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 179. Netherlands Shingles Treatments, by End User USD Million (2025-2030)
  • Table 180. Rest of Europe Shingles Treatments, by Type USD Million (2025-2030)
  • Table 181. Rest of Europe Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 182. Rest of Europe Shingles Treatments, by End User USD Million (2025-2030)
  • Table 183. MEA Shingles Treatments, by Country USD Million (2025-2030)
  • Table 184. MEA Shingles Treatments, by Type USD Million (2025-2030)
  • Table 185. MEA Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 186. MEA Shingles Treatments, by End User USD Million (2025-2030)
  • Table 187. Middle East Shingles Treatments, by Type USD Million (2025-2030)
  • Table 188. Middle East Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 189. Middle East Shingles Treatments, by End User USD Million (2025-2030)
  • Table 190. Africa Shingles Treatments, by Type USD Million (2025-2030)
  • Table 191. Africa Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 192. Africa Shingles Treatments, by End User USD Million (2025-2030)
  • Table 193. North America Shingles Treatments, by Country USD Million (2025-2030)
  • Table 194. North America Shingles Treatments, by Type USD Million (2025-2030)
  • Table 195. North America Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 196. North America Shingles Treatments, by End User USD Million (2025-2030)
  • Table 197. United States Shingles Treatments, by Type USD Million (2025-2030)
  • Table 198. United States Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 199. United States Shingles Treatments, by End User USD Million (2025-2030)
  • Table 200. Canada Shingles Treatments, by Type USD Million (2025-2030)
  • Table 201. Canada Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 202. Canada Shingles Treatments, by End User USD Million (2025-2030)
  • Table 203. Mexico Shingles Treatments, by Type USD Million (2025-2030)
  • Table 204. Mexico Shingles Treatments, by Route of Administration USD Million (2025-2030)
  • Table 205. Mexico Shingles Treatments, by End User USD Million (2025-2030)
  • Table 206. Research Programs/Design for This Report
  • Table 207. Key Data Information from Secondary Sources
  • Table 208. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Shingles Treatments: by Type USD Million (2018-2023)
  • Figure 5. Global Shingles Treatments: by Route of Administration USD Million (2018-2023)
  • Figure 6. Global Shingles Treatments: by End User USD Million (2018-2023)
  • Figure 7. South America Shingles Treatments Share (%), by Country
  • Figure 8. Asia Pacific Shingles Treatments Share (%), by Country
  • Figure 9. Europe Shingles Treatments Share (%), by Country
  • Figure 10. MEA Shingles Treatments Share (%), by Country
  • Figure 11. North America Shingles Treatments Share (%), by Country
  • Figure 12. Global Shingles Treatments share by Players 2023 (%)
  • Figure 13. Global Shingles Treatments share by Players (Top 3) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. GlaxoSmithKline PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 16. GlaxoSmithKline PLC (United Kingdom) Revenue: by Geography 2023
  • Figure 17. Foamix Pharmaceuticals Ltd (United States) Revenue, Net Income and Gross profit
  • Figure 18. Foamix Pharmaceuticals Ltd (United States) Revenue: by Geography 2023
  • Figure 19. Epiphany Biosciences Inc (United States) Revenue, Net Income and Gross profit
  • Figure 20. Epiphany Biosciences Inc (United States) Revenue: by Geography 2023
  • Figure 21. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Merck & Co. (United States) Revenue: by Geography 2023
  • Figure 23. Astellas Pharma Inc.(Japan) Revenue, Net Income and Gross profit
  • Figure 24. Astellas Pharma Inc.(Japan) Revenue: by Geography 2023
  • Figure 25. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 27. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2023
  • Figure 29. Global Shingles Treatments: by Type USD Million (2025-2030)
  • Figure 30. Global Shingles Treatments: by Route of Administration USD Million (2025-2030)
  • Figure 31. Global Shingles Treatments: by End User USD Million (2025-2030)
  • Figure 32. South America Shingles Treatments Share (%), by Country
  • Figure 33. Asia Pacific Shingles Treatments Share (%), by Country
  • Figure 34. Europe Shingles Treatments Share (%), by Country
  • Figure 35. MEA Shingles Treatments Share (%), by Country
  • Figure 36. North America Shingles Treatments Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline PLC (United Kingdom)
  • Foamix Pharmaceuticals Ltd (United States)
  • Epiphany Biosciences Inc (United States)
  • Merck & Co. (United States)
  • Astellas Pharma Inc.(Japan)
  • Novartis International AG (Switzerland)
  • F. Hoffmann-La Roche AG (Switzerland)
Additional players considered in the study are as follows:
Beijing Minhai Biotechnology Co. (China) , GeneOne Life Science, Inc. (South Korea) , NAL Pharmaceuticals Ltd. (United States) , TSRL, Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 216 Pages 67 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Shingles Treatments Quantitative research analysis
Shingles Treatments Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GlaxoSmithKline PLC (United Kingdom), Foamix Pharmaceuticals Ltd (United States), Epiphany Biosciences Inc (United States), Merck & Co. (United States), Astellas Pharma Inc.(Japan), Novartis International AG (Switzerland) and F. Hoffmann-La Roche AG (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"R&D investment in Drug Development" is seen as one of major influencing trends for Shingles Treatments Market during projected period 2023-2030.
The Shingles Treatments market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Shingles Treatments Report?

Have a Query? Click Here

Other Related Reports

Schizophrenia Treatments Comprehensive Study by Type (Medications, Conventional or Typical Antipsychotic Drugs, Atypical Antipsychotic Drugs, Therapies), End Users (Hospital Pharmacies, Drug Stores, ...
$ 3650
Sarcopenia Treatment Comprehensive Study by Type (Protein Supplement, Vitamin B12 Supplement, Vitamin D & Calcium Supplement, Others), End-users (Hospitals, Clinics, Others), Distribution Channel (Ho...
$ 3350
Critical Limb Ischemia Treatment Comprehensive Study by Type (Medications (Antiplatelet Drugs, Antihypertensive Agents, Lipid-lowering Agents, Others), Endovascular Treatments, Surgery), Application ...
$ 3450
Prostatic Artery Embolization Comprehensive Study by Type (Guidewires, Micro catheters, Microspheres), Application (Hospitals, Ambulatory Surgical centers, Specialty clinics) Players and Region - Glo...
$ 3500
Companion Animal Diagnostics Comprehensive Study by Type (Clinical Biochemistry {Clinical Chemistry Analysis, Glucose Monitoring, Blood Glucose Strips}, Immunodiagnostics {Lateral Flow Assays, ELISA ...
$ 3750
Urinary Tract Infection Treatment Comprehensive Study by Disease Type (Cystitis, Urethritis, Pyelonephritis, Vaginitis), Drug (Azoles, Quinolones, Penicillin and combinations, Aminoglycosides, Cepha...
$ 3800